Perrigo Company plc Reports Third Quarter 2016 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/22/2026
- Nasdaq leads Wall Street gains as SpaceX, Super Micro boost AI sentiment
- Meta beats Q3 estimates, approves new nonvoting share class as AI spending surges
- Tesla stock up as automotive gross margin improves, free cash flow turns positive
- SpaceX, Tesla shares rise after Musk says committees exploring possible merger
- Brent falls as Iran's president discusses mediation with Pakistani army chief
- Abbott plans to spin off its nutrition unit as a standalone public company
- Alphabet shares drop ahead of earnings next week
- Nasdaq leads Wall Street gains as SpaceX, Super Micro boost AI sentiment
- Crude Inventory Fell 3.06 Million Barrels Last Week - EIA
- US orders diplomats to depart Saudi Arabia amid Houthi strikes
BofA/Merrill Lynch Upgrades Perrigo Co. (PRGO) to Neutral
November 11, 2016 6:43 AM ESTBofA/Merrill Lynch upgraded Perrigo Co. (NYSE: PRGO) from Underperform to Neutral.
For an analyst ratings summary and ratings history on Perrigo Co. click here. For more ratings news on Perrigo Co. click here.
Shares of Perrigo Co. closed at $89.11 yesterday.
... MorePerrigo (PRGO) Tops Q3 EPS by 7c; Will Explore Strategic Alternatives for Tysabri
November 10, 2016 6:23 AM ESTPerrigo (NYSE: PRGO) reported Q3 EPS of $1.65, $0.07 better than the analyst estimate of $1.58. Revenue for the quarter came in at $1.4 billion versus the consensus estimate of $1.28 billion.
Perrigo also announced that as part of its ongoing business portfolio review, the Company will review strategic alternatives for the rights to the royalty stream from sales of the multiple sclerosis drug Tysabri® (natalizumab).
Perrigo's CEO... More



